Skip to main content
Average ER Wait Times

Methodist Boerne Emergency Center

-- mins

Methodist Children's Hospital

-- mins

Methodist Hospital

-- mins

Methodist Specialty and Transplant Hospital

-- mins

Methodist Stone Oak Hospital

-- mins

Methodist Texsan Hospital

-- mins

Metropolitan Methodist Emergency Center at the Quarry

-- mins

Metropolitan Methodist Hospital

-- mins

Northeast Methodist Hospital

-- mins

Cardio-Oncology Program

Introducing South Texas' First Cardio-Oncology Program

Advanced chemotherapy and radiation treatment have greatly enhanced cancer patient survival. And now, our oncologists and cardiologists are working together to predict, monitor and manage the effect these treatments have on the heart. Methodist Hospital is proud to be the first i South Texas to develop a cardio-oncology progam.

Benefits to Patients

  • Early cardiac testing and regular monitoring can help prevent cardio complications for patients being treated with anthracyclines, radiation or molecular targeted therapies.
  • If patients with previous cancer problems need cancer treatment, this program will allow an early identification adjustment of cardiovascular therapy and closer monitoring to match the clinical course of each patient.

Our Goal: Enhance Treatment with Predictive and Prophalactic Cardiac Monitoring

  • Early detection of patient risks for cardiotoxicity.
  • Early implementation of cardio protective agents.
  • Prevent treatment mitigation of chemotherapeutic agent.
  • Assist oncology with data to help determine the best course of action as treatment proceeds.
  • Provide patients with ongoing cardiovascular care before, during and after treatment.
  • Minimize cardiotoxicity while treatment eliminates cancer.

A Complete Suite of Advanced Testing

  • State-of-the-art ECGs and 3D echocardiography, tests for biomarkers, such as troponin 1 and natriuretic peptide, along with a full range of imaging techniques and diagnostic studies.
  • Monitoring the development of microRNA and intracellular/intramitocondrial biomarkers to facilitate detection of cardiotoxicity.
  • Regular screening and treatment for new patients and long-term cancer survivors on cardiotoxicity and other complications not directly related to cancer therapy, which can occur months or years after oncologic treatment.